PLoS ONE (Jan 2013)

Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers.

  • Mohammad-Ali Jenabian,
  • Mital Patel,
  • Ido Kema,
  • Cynthia Kanagaratham,
  • Danuta Radzioch,
  • Paméla Thébault,
  • Réjean Lapointe,
  • Cécile Tremblay,
  • Norbert Gilmore,
  • Petronela Ancuta,
  • Jean-Pierre Routy

DOI
https://doi.org/10.1371/journal.pone.0078146
Journal volume & issue
Vol. 8, no. 10
p. e78146

Abstract

Read online

Tryptophan (Trp) catabolism into immunosuppressive kynurenine (Kyn) by indoleamine 2,3-dioxygenase (IDO) was previously linked to Th17/Treg differentiation and immune activation. Here we examined Trp catabolism and its impact on Th17/Treg balance in uninfected healthy subjects (HS) and a large cohort of HIV-infected patients with different clinical outcomes: ART-naïve, Successfully Treated (ST), and elite controllers (EC). In ART-naïve patients, increased IDO activity/expression, together with elevated levels of TNF-α and sCD40L, were associated with Treg expansion and an altered Th17/Treg balance. These alterations were normalized under ART. In contrast, Trp 2,3-dioxegenase (TDO) expression was dramatically lower in EC when compared to all other groups. Interestingly, EC displayed a distinctive Trp metabolism characterized by low Trp plasma levels similar to ART-naïve patients without accumulating immunosuppressive Kyn levels which was accompanied by a preserved Th17/Treg balance. These results suggest a distinctive Trp catabolism and Th17/Treg balance in HIV progressors and EC. Thus, IDO-induced immune-metabolism may be considered as a new inflammation-related marker for HIV-1 disease progression.